Publications by authors named "O FitzGerald"
Background: Data on treatment switching directly from tumor necrosis factor inhibitors to tofacitinib in psoriatic arthritis (PsA) are limited. This post hoc analysis assessed efficacy and safety outcomes in patients with PsA who directly switched to tofacitinib in a long-term extension (LTE) study after receiving adalimumab (ADA) in a Phase 3 study, compared with those who continued to receive tofacitinib.
Methods: Patients with active PsA received tofacitinib 5 mg twice daily (BID) or ADA 40 mg once every 2 weeks in a 12-month, randomized, double-blind study (OPAL Broaden) and then continued or switched to tofacitinib 5 mg BID and maintained this dose in an open-label LTE study (OPAL Balance).
It is known that 25%-30% of individuals with cutaneous psoriasis (PsC) will develop psoriatic arthritis (PsA). To date, the reasons for the development of PsA in individuals with PsC have not been identified. Furthermore, there are considerable delays in the diagnosis and treatment of PsA, which lead to joint and bone deformation and chronic pain.
View Article and Find Full Text PDFThe Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) is a nonprofit organization whose mission is to optimize the clinical care of patients with psoriatic disease through multidisciplinary collaboration models. The PPACMAN 2021 Annual Meeting was held virtually on December 11, 2021. In all, 50 stakeholders participated in the meeting including dermatologists, rheumatologists, cardiologists, clinical researchers, patient advocacy representatives, and industry representatives.
View Article and Find Full Text PDFArticle Synopsis
- - The process of DNA double-strand break repair through homologous recombination requires end resection to create a single-stranded DNA template, involving the RAD51 recombinase and other proteins, with BRCA1-BARD1 being crucial for this step.
- - DNA end resection is performed by three key nucleases: EXO1, DNA2 (in partnership with BLM or WRN helicases), working together to resect the DNA ends, while BRCA1-BARD1’s role in regulating this process is critically examined.
- - Research shows that BRCA1-BARD1 directly interacts with EXO1, BLM, and WRN, enhancing their activity, and certain BARD1 mutations impairing DNA
Article Synopsis
- BRCA1 is a special protein that helps prevent cancer by working with another protein called BARD1 to attach something called ubiquitin to other proteins.
- This process helps scientists study how BRCA1-BARD1 and its different versions work by looking at how they attach ubiquitin to histone proteins in DNA.
- The document provides a step-by-step guide on how to isolate DNA, create nucleosome particles, and observe the process of adding ubiquitin in a lab setting.